药物更广泛应用的障碍。
Barriers to the wider adoption of medicinal .
作者信息
Alexander Stephen Ph
机构信息
School of Life Sciences, University of Nottingham Medical School, Nottingham, UK.
出版信息
Br J Pain. 2020 May;14(2):122-132. doi: 10.1177/2049463720922884. Epub 2020 May 29.
Abstract
The use of -based preparations for medicinal use has waxed and waned in the multi-millennial history of human co-existence with the plant and its cultivation. Recorded use of preparations from is effectively as old as recorded history with examples from China, India and Ancient Egypt. Prohibition and restriction of availability allowed a number of alternatives to take the place of preparations. However, there has been a worldwide resurgence in medicinal advocacy from the public. Media interest has been piqued by particular evocative cases. Altogether, therefore, there is pressure on healthcare professionals to prescribe and dispense -based preparations. This review enunciates some of the barriers which are slowing the wider adoption of medicinal .
摘要
在人类与该植物及其种植共存的数千年历史中，药用[植物名称]制剂的使用经历了兴衰起伏。有记录的对[植物名称]制剂的使用几乎与有记录的历史一样古老，中国、印度和古埃及都有相关例证。对其可用性的禁止和限制使得多种替代物取代了[植物名称]制剂。然而，公众对药用[植物名称]的支持在全球范围内再度兴起。一些特别引人关注的案例激发了媒体的兴趣。因此，总体而言，医疗保健专业人员面临着开具和调配基于[植物名称]的制剂的压力。本综述阐明了一些阻碍药用[植物名称]更广泛应用的障碍。
相似文献
1
Barriers to the wider adoption of medicinal .药物更广泛应用的障碍。
Br J Pain. 2020 May;14(2):122-132. doi: 10.1177/2049463720922884. Epub 2020 May 29.
2
History of cannabis and its preparations in saga, science, and sobriquet.传奇、科学及别名中的大麻及其制剂史。
Chem Biodivers. 2007 Aug;4(8):1614-48. doi: 10.1002/cbdv.200790144.
3
A randomised controlled trial of vaporised Δ-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.一项随机对照试验研究了在频繁和不频繁使用大麻的人群中单独使用和联合使用蒸气化 Δ-四氢大麻酚和大麻二酚的效果：急性中毒效应。
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):17-35. doi: 10.1007/s00406-019-00978-2. Epub 2019 Jan 19.
4
Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.大麻、大麻二酚与癫痫——从受体到临床反应
Epilepsy Behav. 2014 Dec;41:277-82. doi: 10.1016/j.yebeh.2014.08.135. Epub 2014 Oct 1.
5
Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.基于模型的分析：联合给予大麻素后经控制蒸发给药的系统生物利用度。
Intern Med J. 2020 Jul;50(7):846-853. doi: 10.1111/imj.14415.
6
Cannabis and epilepsy: An ancient treatment returns to the fore.大麻与癫痫：一种古老的治疗方法再度受到关注。
Epilepsy Behav. 2017 May;70(Pt B):292-297. doi: 10.1016/j.yebeh.2016.09.040. Epub 2016 Dec 15.
7
Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis.基于药用大麻的特制制剂的临床证据。
Pharmaceuticals (Basel). 2021 Jan 21;14(2):78. doi: 10.3390/ph14020078.
8
Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….医用大麻、大麻素及其在医学和头痛治疗中的意义综述：这是一段多么漫长而奇特的旅程啊……
Headache. 2015 Jun;55(6):885-916. doi: 10.1111/head.12570. Epub 2015 May 25.
9
Non-Cannabinoid Metabolites of L. with Therapeutic Potential.具有治疗潜力的拉帕醇非大麻素代谢物。
Plants (Basel). 2021 Feb 20;10(2):400. doi: 10.3390/plants10020400.
10
Cannabis, Cannabidiol Oils and Tetrahydrocannabinol-What Do Veterinarians Need to Know?大麻、大麻二酚油和四氢大麻酚——兽医需要了解什么？
Animals (Basel). 2021 Mar 20;11(3):892. doi: 10.3390/ani11030892.
引用本文的文献
1
Using Cannabis and CBD to Sleep: An Updated Review.使用大麻和大麻二酚助眠：最新综述。
Curr Psychiatry Rep. 2024 Dec;26(12):712-727. doi: 10.1007/s11920-024-01564-7. Epub 2024 Nov 29.
2
Real-world patient experience with medicinal cannabis use for symptom management in an Australian advanced cancer setting: a mixed method, cohort study using the theory of planned behaviour framework.澳大利亚晚期癌症环境下，使用药用大麻治疗症状的真实患者体验：基于计划行为理论框架的混合方法、队列研究。
Support Care Cancer. 2024 Nov 15;32(12):795. doi: 10.1007/s00520-024-09013-0.
3
Perceptions and Preoccupations of Patients and Physicians Regarding Use of Medical Cannabis as an Intervention Against Chronic Musculoskeletal Pain: Results from a Qualitative Study.患者和医生对使用医用大麻作为慢性肌肉骨骼疼痛干预措施的认知与关注：一项定性研究的结果
J Pain Res. 2023 Oct 18;16:3463-3475. doi: 10.2147/JPR.S413450. eCollection 2023.
4
Clinical Research Evidence Supporting Administration and Dosing Recommendations of Medicinal Cannabis as Analgesic in Cancer Patients.支持药用大麻用于癌症患者镇痛的给药及剂量建议的临床研究证据。
J Clin Med. 2022 Dec 30;12(1):307. doi: 10.3390/jcm12010307.
5
'What price do you put on your health?': Medical cannabis, financial toxicity and patient perspectives on medication access in advanced cancer.“你愿意为健康付出什么代价？”：晚期癌症患者对药物获取的看法，包括医用大麻、经济毒性等方面。
Health Expect. 2023 Feb;26(1):160-171. doi: 10.1111/hex.13642. Epub 2022 Nov 6.
6
Medical cannabis, CBD wellness products and public awareness of evolving regulations in the United Kingdom.医用大麻、CBD健康产品与英国公众对不断演变的法规的认知
J Cannabis Res. 2022 Oct 29;4(1):56. doi: 10.1186/s42238-022-00165-6.
7
Medical Cannabis: Toward a New Policy and Health Model for an Ancient Medicine.医用大麻：迈向一种古老医学的新政策与健康模式。
Front Public Health. 2022 May 27;10:904291. doi: 10.3389/fpubh.2022.904291. eCollection 2022.
8
Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years.澳大利亚医用大麻处方：头五年的趋势分析
Front Pharmacol. 2022 May 10;13:885655. doi: 10.3389/fphar.2022.885655. eCollection 2022.
9
Expanding Research on Cannabis-Based Medicines for Liver Steatosis: A Low-Risk High-Reward Way Out of the Present Deadlock?拓展基于大麻的药物治疗脂肪性肝病的研究：走出当前僵局的低风险高回报之路？
Cannabis Cannabinoid Res. 2023 Feb;8(1):5-11. doi: 10.1089/can.2022.0014. Epub 2022 Apr 13.
10
Real World Evidence in Medical Cannabis Research.真实世界证据在医用大麻研究中的应用。
Ther Innov Regul Sci. 2022 Jan;56(1):8-14. doi: 10.1007/s43441-021-00346-0. Epub 2021 Nov 8.
本文引用的文献
1
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.植物大麻素酸的药代动力学和大麻二酚酸在 Dravet 综合征小鼠模型中的抗惊厥作用。
J Nat Prod. 2019 Nov 22;82(11):3047-3055. doi: 10.1021/acs.jnatprod.9b00600. Epub 2019 Nov 5.
2
Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.联合给予大麻二酚和氯巴占：药效学和药代动力学相互作用的临床前证据。
Epilepsia. 2019 Nov;60(11):2224-2234. doi: 10.1111/epi.16355. Epub 2019 Oct 17.
3
Absence of Entourage: Terpenoids Commonly Found in Do Not Modulate the Functional Activity of Δ-THC at Human CB and CB Receptors.无伴随物：大麻中常见的萜类化合物不会调节Δ-THC在人CB1和CB2受体上的功能活性。
Cannabis Cannabinoid Res. 2019 Sep 23;4(3):165-176. doi: 10.1089/can.2019.0016. eCollection 2019.
4
Probing the antioxidant activity of Δ-tetrahydrocannabinol and cannabidiol in Cannabis sativa extracts.探究大麻提取物中 Δ-四氢大麻酚和大麻二酚的抗氧化活性。
Analyst. 2019 Aug 5;144(16):4952-4961. doi: 10.1039/c9an00890j.
5
Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents.大麻二酚通过啮齿动物的 CB1 和 CB2 受体机制抑制蔗糖的自我给药。
Addict Biol. 2020 Jul;25(4):e12783. doi: 10.1111/adb.12783. Epub 2019 Jun 19.
6
A Survey of Hospice Professionals Regarding Medical Cannabis Practices. Hospice 专业人员医疗大麻实践情况调查。
J Palliat Med. 2019 Oct;22(10):1208-1212. doi: 10.1089/jpm.2018.0535. Epub 2019 May 16.
7
Terpenes in Cannabis sativa - From plant genome to humans.大麻中的萜烯——从植物基因组到人类。
Plant Sci. 2019 Jul;284:67-72. doi: 10.1016/j.plantsci.2019.03.022. Epub 2019 Apr 4.
8
Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy.药物治疗抵抗性癫痫患儿多次使用医药级合成大麻素的药代动力学和耐受性。
CNS Drugs. 2019 Jun;33(6):593-604. doi: 10.1007/s40263-019-00624-4.
9
Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol.化疗诱导的恶病质会扰乱下丘脑和全身的脂肪胺，而大麻萜酚则可以减轻这种影响。
J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):844-859. doi: 10.1002/jcsm.12426. Epub 2019 Apr 29.
10
Quantitative determination of CBD and THC and their acid precursors in confiscated cannabis samples by HPLC-DAD.采用高效液相色谱-二极管阵列检测器（HPLC-DAD）对没收大麻样品中的大麻二酚（CBD）、四氢大麻酚（THC）及其酸性前体进行定量测定。
Forensic Sci Int. 2019 Jun;299:142-150. doi: 10.1016/j.forsciint.2019.03.046. Epub 2019 Apr 5.
Zotero 插件